Introduction
Post-transplantation thrombotic microangiopathy (TMA), first described nearly 30 years ago, 1 remains an infrequent, but frustrating complication of SCT. The etiologies of this syndrome are thought to be diverse and management remains difficult, as many patients fail to respond to treatments that are beneficial in nontransplant-associated TMA.
Pathologic and clinical features
TMA is a pathologic term, describing arteriolar thrombi associated with intimal swelling and fibrinoid necrosis of the vessel wall. 2 The microscopic injury results from a spectrum of insults that can cause intravascular platelet activation with the subsequent formation of platelet-rich thrombi within the microcirculation. This process consumes platelets and induces mechanical damage to blood cells as they impact microthrombi or fibrin strands obstructing the microcirculation, resulting in the clinical hallmarks of TMA: microangiopathic hemolytic anemia and thrombocytopenia. TMA is characteristic of the clinical syndromes thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS), but is also seen in disorders such as systemic sclerosis, systemic lupus erythematosus, antiphospholipid antibody syndrome, malignant hypertension, pre-eclampsia, a wide range of infections (including bacterial, fungal and other viral agents), metastatic carcinoma and the post-SCT state. 2, 3 The clinical presentation in any individual patient invariably includes schistocytes on the peripheral blood smear, and usually includes thrombocytopenia as well. Characteristic biochemical abnormalities include increased serum lactate dehydrogenase (LDH), decreased serum haptoglobin and indirect hyperbilirubinemia. Hemoglobinuria, either frank or microscopic, frequently occurs. Other manifestations largely depend on the organ microcirculation affected. For instance, in HUS, renal dysfunction, caused by microthrombi in glomerular capillaries and arterioles, predominates, with relative sparing of other organs. Patients with classical TTP have more widespread involvement of the microcirculation resulting in renal insufficiency, myocardial ischemia, neurological abnormalities and possibly other organ dysfunction. The classic diagnostic pentad (three required for diagnosis) in idiopathic TTP includes microangiopathic hemolytic anemia, thrombocytopenia, fever, renal dysfunction and neurological abnormalities. 3 Overlap between TTP and HUS syndromes is common, and the disorders are sometimes identified generically by the acronym TTP-HUS. 3 Presentation of transplantation-associated thrombotic microangiopathy (TA-TMA) is similar to other forms of TMA and likewise is heterogeneous. The diagnosis frequently is complicated by multiple potential etiologies for the clinical findings. The vast majority of patients in the post-transplant period have persistent anemia, thrombocytopenia and fever; renal dysfunction and subtle neurologic abnormalities also are possible. The findings associated with TMA may be difficult to distinguish from similar phenomena caused by delayed engraftment, infection, medications, GVHD or any other disorders associated with the SCT process. 4 In addition, much like the nontransplant-associated counterparts, the severity of TA-TMA may range from asymptomatic to fulminant. 5 
Diagnostic criteria
Recently, two sets of diagnostic criteria have been proposed in an effort to standardize definitions for the purposes of diagnosis and clinical trial development (Table 1) . 6, 7 These criteria help clarify salient clinical features of TA-TMA; however, they fail to distinguish primary TTP-HUS from secondary causes of TMA that may be present in hematopoietic stem cell transplant recipients (see Pathophysiology below). As discussed below, differentiating between primary and secondary causes of TMA in the post-transplantation state, if possible, may be critical for making rational treatment decisions.
Incidence and risk factors
The incidence of TA-TMA is difficult to discern from the literature. George et al. 4 reported the most complete review, to date, of all available published case series of TTP or HUS after allogeneic transplantation. They found a frequency of diagnosis ranging between 0.5 and 63.6%, and 28 distinct sets of diagnostic criteria in 35 published series, encompassing a total of 447 cases of TTP-HUS. Furthermore, they identified 35 autopsy reports among the 447 reported cases. Three of the autopsies attributed death to HUS due to the observation of isolated renal TMA. The remaining 32 deaths were attributed to other causes, the most common of which was systemic infection, including Aspergillus species, cytomegalovirus (CMV), adenovirus, human parvovirus B19 and human herpesvirus-6 (HHV). Eleven autopsies explicitly stated that there was no evidence for TTP-HUS, and none of the autopsy reports described systemic microthrombosis. 4 These findings underscore the challenge of accurately diagnosing TTP-HUS in stem cell transplant recipients, and suggest that the clinical features of TMA attributed to TTP-HUS in the cases reviewed represent processes secondary to transplantrelated complications rather than primary TTP-HUS.
A variety of potential risk factors for the development of TMA after SCT have been proposed, as shown in Table 2 . None of these risk factors, however, has been consistently supported by the available case series, as described by George and colleagues. 4 
Pathophysiology
Idiopathic TTP Classic idiopathic TTP has been attributed in large part to deficient activity of a metalloproteinase responsible for cleaving ultra large von Willebrand factor (vWF) multimers before being exported from endothelial cells in vivo. 24, 25 This protease was found to be a member of the 'a disintegrin and metalloprotease with thrombospondin type 1 repeats' family subsequently named ADAMTS13. [26] [27] [28] [29] [30] /l or a 50% or greater decrease from previous counts) (3) Sudden and persistent increase in LDH (4) Decrease in hemoglobin concentration or increased red blood cell transfusion requirement (5) Decrease in serum haptoglobin concentration Abbreviations: LDH ¼ lactate dehydrogenase; TMA ¼ thrombotic microangiopathy; TA-TMA ¼ transplantation-associated thrombotic microangiopathy. a Doubling of serum creatinine from baseline (baseline ¼ creatinine before hydration and conditioning) or 50% decrease in creatinine clearance from baseline.
Table 2
Potential risk factors for development of TA-TMA
Risk factor References
Older age 8 Female sex [8] [9] [10] [11] Advanced primary disease 10, 12 Unrelated donor transplants [9] [10] [11] [13] [14] [15] [16] Nonmyeloablative transplants (fludarabine-based regimens) 15, 17 High-dose busulfan (16 mg/kg) 18 HLA mismatch (one or more loci) 10 Total body irradiation 11, 13 Cyclosporine (CsA) 1, 19, 20 Tacrolimus (FK506) 18, 21 CsA or FK506+sirolimus 22, 23 Acute GVHD 8, 10, 11, 16, 20 Infection (if any) 10, 16 Abbreviations: GVHD ¼ graft-versus-host disease; HLA ¼ human leukocyte antigen; TA-TMA ¼ transplantation-associated thrombotic microangiopathy.
The ADAMTS13-deficient activity is due to either a true deficiency of the enzyme or an inhibitory antibody, 25, 31 and is generally severe (o5% activity); however, the incidence of severe ADAMTS13 deficiency in laboratory testing among patients with idiopathic TTP is variable, ranging in published series from 33 to 100%. 32 It is believed that in most cases, the pathogenesis of idiopathic TTP is an autoantibody that inhibits ADAMTS13, allowing uncleaved vWF multimers to clump platelets, activating them and leading to propagation of platelet-rich thrombi in the microvasculature. The microangiopathic hemolytic anemia is thought to be caused by intravascular shearing of RBCs upon partially occlusive vWF-platelet aggregates in the microcirculation. 33 These combined effects ultimately result in the microangiopathic hemolytic anemia, thrombocytopenia and other features classically associated with TTP. 32 For patients with idiopathic TTP with in vitro ADAMTS13 activity45%, the primary etiology of the disorder is less clear; however, unidentified insults resulting in secondary, rather than primary, TMA may be causative in these cases. This latter situation, in fact, may be the case for most instances of TA-TMA, in which severe ADAMTS13 deficiency is uncommon and numerous other insults have been implicated in the development of TMA (see below). Plasma exchange, the standard modality for treatment of idiopathic TTP, presumably exerts its beneficial effect in part by restoring sufficient ADAMTS13 activity (by removing inhibitory autoantibody, restoring ADAMTS13 levels or both), to cleave the ultra-large vWF multimers and reverse the microthrombotic process. 34 Hemolytic-uremic syndrome Hemolytic-uremic syndrome refers to TMA that primarily affects the kidney, often causing oliguric or anuric renal failure. 3 This disorder classically follows a diarrheal illness caused by Gram-negative bacilli producing Shiga toxin (D þ HUS). 3 In D þ HUS, circulating Shiga toxin binds to glycosphingolipid globotriaosylceramide found on renal glomerular endothelial, mesangial and tubular epithelial cells, resulting in endothelial injury that generates thrombin, inducing thrombosis in the microvasculature. 35 Fibrinolysis also appears to be inhibited due to increased levels of plasminogen activator inhibitor-1 (PAI-1). 35 The end result is microthrombosis selectively involving the renal microvasculature. Unlike idiopathic TTP, the thrombotic lesion in D þ HUS is often rich in fibrin and incorporates few platelets. 3 TMA associated with predominantly oliguric renal failure in the absence of a diarrheal illness or other predisposing condition is commonly referred to as DÀ, or atypical, HUS. 3 The causes of DÀ HUS are thought to be heterogenous, but recent studies in non-Shiga toxinassociated HUS indicate that a sizable minority may be due to mutations in several proteins responsible for regulating the alternative complement pathway, including complement factor H (CFH), membrane cofactor protein (MCP) and factor I (IF). 3, 36 It has been proposed that such mutations predispose carriers to the development of HUS in the setting of complement activation by insults such as infections or endothelial injury caused by drugs or systemic illnesses by impairing protection of the endothelial surface. Impairment of endothelial cell protection could result in membrane attack, complex formation on endothelial cells, and recruitment of inflammatory cells, resulting in further injury to endothelial cells. 36 Endothelial cell injury results in platelet adhesion and the formation of arteriolar microthrombi. 36 Although the clinical manifestations of idiopathic TTP and HUS often overlap, D þ HUS and DÀ HUS are generally secondary processes associated with a predisposing insult, are virtually never associated with severe ADAMTS13 deficiency, and generally respond poorly to plasma exchange. 3, 32 Secondary TMA Although severely deficient ADAMTS13 activity appears to be pathogenetic in the development of TMA in most patients with idiopathic TTP, this finding has not been universal in most other instances of TMA. Data from the Oklahoma TTP-HUS registry demonstrated that severe ADAMTS13 deficiency was not present in 92 patients with identifiable secondary causes of TTP-HUS, such as preeclampsia, systemic infection, diarrhea caused by Shiga toxin-producing Escherichia coli, medications (including quinine, mitomycin C, CYA, ticlopidine, gemcitabine, pentostatin and carmustine), systemic malignancy or hematopoietic or solid organ transplantation. 37 Several small retrospective studies of TA-TMA encompassing a total of 33 hematopoietic stem cell recipients also suggest that severe ADAMTS13 deficiency may be rare among this patient population. 15, [38] [39] [40] More recently, two prospective reports of ADAMTS13 activity in hematopoietic cell transplant patients suggested that the majority of transplant recipients experience a decrease in ADAMTS13 activity that occurs after conditioning and may persist for several weeks; however, severe ADAMTS13 activity was rare. 41, 42 Only one of the 74 patients reported in these studies had ADAMTS13 activityo10% at any time during follow-up; this patient also was only one of the five patients reported to have developed TA-TMA. 41, 42 The number of patients affected by TA-TMA in these studies is too small to be able to draw firm conclusions regarding the predictive ability of ADAMTS13 levels in hematopoietic stem cell recipients, but these data do suggest that, unlike classic idiopathic TTP, ADAMTS13 deficiency alone is unlikely to be a primary component of the pathophysiology of TA-TMA. This indicates that TA-TMA may be more similar to HUS syndromes than classic TTP, and is likely a secondary process.
Abnormalities of vascular endothelium
Abnormalities of the vascular endothelium, independent of ADAMTS13 activity, are thought to be critical to the pathogenesis of TMA in many settings, including the posttransplantation state. Support for this concept came when Laurence and co-workers 43 showed that apoptosis in microvascular endothelial cells can be induced by plasma from patients with idiopathic TTP and DÀ HUS in vitro. 44 They also demonstrated enhanced apoptosis of microvascular endothelial cells in vivo in patients with TTP. 45 These studies revealed induction of Fas (CD95) in endothelial cells after exposure to TTP plasma, which results in apoptosis of human cells. [43] [44] [45] On the basis of their findings, they proposed that induction of endothelial cell injury was an important component of the pathogenesis of TMA in patients with idiopathic TTP and DÀ HUS. Cohen et al. 46 proposed that endothelial injury is pathogenetic of TA-TMA as well after they demonstrated absent endothelial prostacyclin (PGI 2 ) release and scanning EM evidence of endothelial cell damage in patients with TMA after allogeneic transplantation. They also found elevated vWF antigen levels with normal vWF multimer patterns in their patients, consistent with endothelial injury. 46 Increased levels of other plasma markers associated with endothelial cell injury, including thrombomodulin (TM), PAI-1 and soluble intercellular adhesion molecule 1 (ICAM-1) have been observed in plasma studies by others as well. [47] [48] [49] [50] [51] [52] Elevated levels of IL-1, tumor necrosis factor-a (TNF-a), IFN-g and IL-8, all of which may be directly toxic to endothelial cells or enhance inflammation-mediated tissue injury, also have been reported following transplant conditioning and in the settings of acute GVHD and hepatic veno-occlusive disease (VOD). 5, [53] [54] [55] [56] These findings imply that endothelial injury is critical to the development of TMA in the hematopoietic SCT setting.
It has been proposed that endothelial cell microparticles may also contribute to the development of microangiopathy. Endothelial cell activation and apoptosis have been associated with generation of endothelial microparticles that may be released into the circulation. 57, 58 Release of endothelial microparticles has been associated with procoagulant activity. 59, 60 This procoagulant activity appears to be associated with expression of negatively charged phosphatidylserine and tissue factor on the surface of microparticles, 59 as well as the presence of vWF, including ultra-large vWF multimers. 61, 62 Furthermore, endothelial microparticles induce platelet aggregation, and, thus, by inducing microthrombosis could predispose to TMA. 62 In addition, endothelial cell microparticles may have proinflammatory effects that contribute to further endothelial cell activation or apoptosis. 57 Increased production of microparticles with an endothelial cell activation phenotype has been demonstrated in idiopathic TTP. 61 Very little data concerning the release of endothelial microparticles in the course of hematopoietic SCT exist; however, a recent report suggests that endothelial microparticles expressing markers of endothelial activation (CD62 and annexin V) increase in the setting of acute GVHD, but not immediately following nonmyeloablative conditioning regimens. 63 Increases in circulating platelet-and monocyte-derived microparticles have also been observed in the peritransplantation period, including in one case of TA-TMA. 64 Proposed mechanisms for endothelial injury in hematopoietic stem cell transplant recipients include high-dose chemotherapy, [65] [66] [67] [68] [69] [70] radiotherapy, 71 infections (CMV, HHV-6 and Aspergillus) 52, 72, 73 and GVHD. 47, 49, [72] [73] [74] [75] In addition, calcineurin inhibitors used for GVHD prophylaxis have been associated with increased production of thromboxane A 2 (TXA 2 ) and decreased production of PGI 2 (CsA), 76, 77 as well as direct toxicity to the endothelium (CYA and possibly tacrolimus). [78] [79] [80] [81] [82] [83] The addition of sirolimus to a calcineurin inhibitor has been associated with potentiation of these effects. 22, 23, 84 The net effect of the changes to endothelial integrity induced by these insults may be the generation of a procoagulant endothelium, ultimately leading to a predilection for secondary TMA. The variety of potential endothelial insults resulting in altered endothelial function may explain why, although significantly more common in allogeneic transplantation, TA-TMA also occurs in autologous transplantationseveral of the inciting agents (high-dose chemotherapy, radiotherapy and infection) are frequently part of the clinical course in autologous SCT as well. 15, 72, 85, 86 A simplified diagram of the possible interactions contributing to development of a thrombophilic endothelium in TA-TMA is shown in Figure 1 .
Patient-specific factors in TA-TMA Other patient-specific characteristics may also predispose to endothelial injury in the setting of hematopoietic SCT. Mutations in complement regulators, such as those identified in some patients with DÀ HUS, for instance, may contribute to the development of TA-TMA in some cases. These mutations (and possibly others yet to be identified) likely occur at a frequency less than that of TA-TMA, but in affected patients, they may increase the risk of developing TA-TMA by increasing the susceptibility of the endothelium to the insults associated with SCT noted above. Thus far, no studies of complement regulator protein mutations have been reported in hematopoietic cell transplant recipients.
Prognosis
TA-TMA is a feared complication of SCT due to its poor prognosis. Owing to variations in case definitions in the literature, the mortality rate associated with development of TA-TMA is difficult to discern; however, a mortality rate in excess of 60% is likely. 4 The high rate of mortality is multifactorial, including direct complications of TMA such as renal failure or myocardial and brain ischemia, as well as serious concomitant disorders (GVHD, infection, and so on). A few series have evaluated clinical features that may have prognostic implications in patients who develop TA-TMA. These are summarized in Table 3 . Vigilance on the part of treating physicians may be crucial to outcomes as well, because delays in diagnosis and institution of appropriate therapy may also contribute to the high mortality rate.
Treatment
Currently, there is no consensus regarding the approach to treatment of TA-TMA, and no randomized clinical trials exist. As indicated above, most cases of TA-TMA are probably secondary events associated with endothelial insults, rather than primary disorders caused by an inhibitory antibody or an enzyme deficiency as in idiopathic TTP. As a result, conventional treatments for idiopathic TTP may be ineffective. Instead, most clinicians initially attempt to eliminate possible causative conditions. Potential culprit medications, such as CYA, tacrolimus and sirolimus should be withdrawn immediately if TA-TMA is suspected. In the setting of the need for continuing immunosuppression, alternative agents, such as corticosteroids, mycophenolate mofetil, azathioprine or others, are instituted. Switching from CYA to tacrolimus is unlikely to be beneficial. 87 Aggressive treatment of GVHD and opportunistic infections is essential as mortality in TA-TMA is often due to these complications of transplantation rather than TMA itself. 4, 5, [8] [9] [10] [11] [12] [13] [14] [15] Plasma exchange Despite limited data, many centers employ plasma exchange (PE) as part of the management of TA-TMA. Response rates to PE in TA-TMA are significantly lower (less than 50%) 5 compared to that reported for idiopathic TTP, which are approximately 75%. 88 In addition, mortality rates in TA-TMA treated with PE generally exceed 80%, as compared to 20% for idiopathic TTP. 5, 6, 15, 32, 88 This striking difference in mortality rates may reflect, in part, the significant comorbidity of the post-transplantation state; however, it also supports the available data that indicate that TA-TMA results from mechanisms distinct from those involved in idiopathic TTP. In other words, while removing an autoantibody-inhibiting ADAMTS13 activity and replenishing ADAMTS13 levels via plasma exchange may reverse the underlying mechanism driving idiopathic TTP, this therapy may be ineffective if the driving force behind the TMA following hematopoietic SCT is independent of ADAMTS13 activity. Furthermore, major complications associated with pheresis catheters or plasma exposure, including systemic infection, thrombosis, hemorrhage, pneumothorax, pericardial tamponade, hypoxia, hypotension, serum sickness and anaphylaxis, occur in approximately 28% of patients treated with PE. [89] [90] [91] The mortality rate directly attributable to plasma exchange in this series was 2.4%. 91 Plasma exchange in conjunction with staphylococcal protein A immunoadsorption may be somewhat more effective than plasma exchange alone, but extensive investigations have not been performed and the mechanism of this maneuver in reversing TA-TMA is not clear. 92, 93 The absence of convincing efficacy data from the published series and the significant complication rate have prompted some -authors to caution against routine implementation of PE in TA-TMA until other etiologies of TMA (infection, GVHD and so on) can be excluded or until data from clinical trials become available. 6, 94 Other therapeutic approaches Several other approaches have been reported in the literature, but the results are mixed (Table 4) . Wolff et al. 95 described CR of TMA in 9 of 13 patients with GVHD and TMA who were switched from a calcineurin inhibitor to the anti-CD25 antibody daclizumab for Table 3 Poor prognostic factors in TA-TMA
Prognostic factor References
AgeX18 years 11 Unrelated or haploidentical donor 11 Elevated TMA index (LDH/platelet ratio) 11 Schistocyte count (45-10/hpf) 75 TMA in the absence of sirolimus exposure treatment of GVHD. Five of the patients who had CR of TMA also attained CR of GVHD, four of whom remained alive after at least 266 days post transplant. 95 The fifth patient who achieved CR of both TMA and GVHD died of primary disease relapse, and the remaining eight patients died from infections, GVHD or multiorgan failure. 95 Defibrotide, a polydeoxyribonucleotide salt known to have antithrombotic and thrombolytic effects and that inhibits TNF-a-mediated endothelial cell apoptosis in vitro, 100 has been shown to improve outcomes in hepatic VOD following hematopoietic cell transplantation. 55, 56 Owing to similarities between VOD and TA-TMA, Corti et al.
96
treated 12 patients with defibrotide for TA-TMA. Six patients achieved complete and three partial resolution of TMA. Au and colleagues 97 recently reported five consecutive patients with TA-TMA refractory to treatment with plasma exchange and high-dose corticosteroids subsequently treated with 4 weekly doses of rituximab. Four of these patients experienced CR of TMA; one responder later died from sepsis while still in remission and the nonresponder died of multiorgan failure within 3 weeks of diagnosis of TMA. 97 The potential mechanism of action for rituximab in TA-TMA is unknown, but may be related to an immunomodulatory effect of this drug. 97 Takatsuka and colleagues 98 administered eicosapentaenoic acid (EPA) in the peritransplant period to reduce the incidence of inflammation-related complications of hematopoietic SCT, such as TMA. Sixteen consecutive patients were evaluated, seven of whom received EPA beginning 3 weeks before unrelated donor allogeneic transplant, and continuing until approximately 180 days following transplantation; nine patients did not receive EPA. All patients received similar conditioning and GVHD prophylaxis regimens. TMA developed in four untreated patients and five untreated patients died; however, none of the treated patients developed TMA and all were alive at least 143 days following transplant. Furthermore, systemic inflammatory cytokine levels, including leukotriene B 4 , TXA 2 and PGI 2 , were significantly lower in treated patients, as were TNF-a, IFN-g, IL-10 and surrogates for endothelial damage, including TM and PAI-1. 98 These data suggest that modulation of inflammatory cytokines and vascular endothelial dysfunction with prophylactic administration of EPA may decrease complications, including TMA, in allogeneic SCT. These findings, however, need to be corroborated in a larger prospective trial. Finally, a single case report indicates successful use of transdermal isosobide tape as a nitric oxide donor for the management of TA-TMA. 99 TNF-a inhibitors, such as etanercept and infliximab, have demonstrated activity in the management of acute GVHD, and, in theory, might be beneficial in TA-TMA as well. [101] [102] [103] [104] [105] [106] Unfortunately, none of the studies of TNF-a inhibitors in this setting report the incidence of TMA in the study populations before treatment, and only one 103 reports a single patient who died from complications of TMA following treatment with infliximab. A potential limiting factor to treatment with TNF-a inhibitors is an increased risk of opportunistic infections, including invasive fungal and viral infections.
102-105

Future directions
There is increasing evidence to suggest that TA-TMA represents a final common pathway for endothelial injury from a variety of potential insults, including conditioning regimens, calcineurin inhibitors, acute GVHD and opportunistic infections.
In many cases, multiple factors likely contribute simultaneously to the development and propagation of TMA. Ongoing work in the laboratory and clinic, including further research investigating the mechanisms of endothelial injury and endothelial microparticle generation, will aid in understanding the pathophysiology of TMA. It remains to be seen whether monitoring for evidence of endothelial injury by detection of endothelial microparticles or protein concentration changes that occur in the setting of endothelial injury (such as increased levels of vWF, TM and PAI-1) will be useful in detecting early onset of TMA. Early detection and earlier intervention could provide opportunities to identify reversible causes of endothelial injury, prevent development of frank TMA and improve outcomes, although this also remains to be proven. In addition to the agents used to treat TA-TMA described above, there are a number of compounds being developed or already in use for other disorders that may be useful for attenuating the effects of endothelial injury in the setting of hematopoietic SCT (see Table 5 ). These include statins, which reduce the endothelial inflammatory response to myocardial ischemia and percutaneous interventions [107] [108] [109] [110] and iloprost, a prostacyclin analogue that has been shown to reduce plasma markers of endothelial cell activation and injury in patients with rheumatoid arthritis. 111 Endothelin receptor antagonists, such as bosentan, have been shown in vitro to ameliorate microvascular injury induced by CYA 112 and to protect against ischemia/ reperfusion induced endothelial injury in vivo. 113 Edaravone is a free radical scavenger that has been piloted in myocardial ischemia and cerebrovascular accident patients and has been shown to inhibit vascular endothelial cell injury in response to ischemia as well as augment nitric oxide synthesis and reduce thrombogenesis associated with damaged endothelium in animal models. 114 Interestingly, edaravone has also demonstrated activity in preventing cisplatin-induced renal toxicity in animal models, and may have a role in mediating toxicities associated with conditioning. 115 At present edaravone is commercially available only in Japan, and is licensed for the treatment of ischemic stroke.
As our understanding of the mechanisms of endothelial injury and inflammation in the hematopoietic SCT setting increases, rational implementation of strategies that allow earlier diagnosis and abrogation of the effects of endothelial injury may improve outcomes for patients afflicted by this devastating complication of SCT. 
